Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy – Morbidity and outcome results
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,Hematology
Reference24 articles.
1. Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness;Norderhaug;Eur Urol,2003
2. Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide;Ellis;Brachytherapy,2007
3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality;Kollmeier;Int J Radiat Oncol Biol Phys,2003
4. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy;Grimm;Int J Radiat Oncol Biol Phys,2001
5. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer;Potters;J. Urol.,2005
Cited by 36 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience;Current Oncology;2023-06-09
2. Novel Porous Polycatenated Iodo–Cadmium Coordination Polymer for Iodine Sorption and Electrical Conductivity Measurement;Crystal Growth & Design;2019-02-20
3. Prostate-specific antigen bounce in patients treated before 60 years old by iodine 125 brachytherapy for prostate cancer is frequent and not a prognostic factor;Brachytherapy;2018-11
4. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study;Brachytherapy;2018-03
5. Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer;Journal of Contemporary Brachytherapy;2018
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3